Published in Arthritis Res on March 31, 2000
Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis (2003) 3.33
A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther (2004) 2.72
Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis (2004) 2.71
Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis (2006) 2.68
Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther (2004) 2.58
Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis (2003) 2.53
Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis (2005) 2.35
Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol (2005) 2.28
N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol (2011) 2.18
Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res (2001) 2.18
Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med (2008) 2.17
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis (2004) 2.15
Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther (2004) 2.05
Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther (2005) 2.03
Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther (2005) 2.02
Roles of B cells in rheumatoid arthritis. Arthritis Res Ther (2003) 1.57
Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis (2005) 1.57
Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum (2009) 1.56
Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin Rheumatol (2006) 1.54
Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum (2008) 1.48
Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis (2004) 1.46
A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population. Ann Rheum Dis (2004) 1.36
Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol (2006) 1.34
Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study. Ann Rheum Dis (2001) 1.33
Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther (2006) 1.27
Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther (2006) 1.24
Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res (2000) 1.23
Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res (2002) 1.22
Regulation of histone modification and chromatin structure by the p53-PADI4 pathway. Nat Commun (2012) 1.20
Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis (2004) 1.19
Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol (2006) 1.18
Citrullination, a possible functional link between susceptibility genes and rheumatoid arthritis. Arthritis Res Ther (2003) 1.17
Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis (2006) 1.15
Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis. Ann Rheum Dis (2001) 1.15
Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther (2008) 1.11
Human antibodies induce arthritis in mice deficient in the low-affinity inhibitory IgG receptor Fc gamma RIIB. J Exp Med (2006) 1.08
The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) (2011) 1.07
Autoimmunity against fibrinogen mediates inflammatory arthritis in mice. J Immunol (2009) 1.06
ERK-dependent T cell receptor threshold calibration in rheumatoid arthritis. J Immunol (2009) 1.06
Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts. Clin Exp Immunol (2005) 1.06
Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol (2004) 1.05
Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther (2009) 1.04
Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol (2007) 1.04
Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther (2005) 1.03
Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis. Rheumatol Int (2008) 1.03
Biomarkers for rheumatoid arthritis: making it personal. Scand J Clin Lab Invest Suppl (2010) 1.00
Proteoglycan-induced arthritis and recombinant human proteoglycan aggrecan G1 domain-induced arthritis in BALB/c mice resembling two subtypes of rheumatoid arthritis. Arthritis Rheum (2011) 0.99
Anti-Sa antibodies: prognostic and pathogenetic significance to rheumatoid arthritis. Arthritis Res Ther (2004) 0.98
Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis (2002) 0.95
Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology. Am J Transl Res (2012) 0.93
Identification of novel autoantigen in the synovial fluid of rheumatoid arthritis patients using an immunoproteomics approach. PLoS One (2013) 0.92
A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol (2007) 0.90
The role and clinical implications of G6PI in experimental models of rheumatoid arthritis. Arthritis Res Ther (2004) 0.90
Why do we not have a cure for rheumatoid arthritis? Arthritis Res (2002) 0.90
Differential proteomic analysis of synovial fluid from rheumatoid arthritis and osteoarthritis patients. Clin Proteomics (2014) 0.89
Greater prevalence of seropositivity for anti-cyclic citrullinated peptide antibody in unaffected first-degree relatives in multicase rheumatoid arthritis-affected families. Korean J Intern Med (2012) 0.88
Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis. Arthritis Res Ther (2003) 0.88
Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren's syndrome, and Wegener's granulomatosis. Clin Rheumatol (2005) 0.87
A citrullinated fibrinogen-specific T cell line enhances autoimmune arthritis in a mouse model of rheumatoid arthritis. J Immunol (2013) 0.87
Meta-analysis: diagnostic value of serum anti-mutated citrullinated vimentin antibodies in patients with rheumatoid arthritis. Rheumatol Int (2010) 0.87
Antibodies directed to cyclic citrullinated peptides in familial Mediterranean fever. Rheumatol Int (2009) 0.87
New autoantibodies in early rheumatoid arthritis. Arthritis Res Ther (2013) 0.86
Antibodies against cyclic citrullinated peptides in infectious diseases--a systematic review. Clin Rheumatol (2010) 0.86
Clinical biomarkers and pathogenic-related cytokines in rheumatoid arthritis. J Immunol Res (2014) 0.86
Peptide-coated nanotube-based biosensor for the detection of disease-specific autoantibodies in human serum. Biosens Bioelectron (2007) 0.85
Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis. Curr Opin Immunol (2013) 0.83
Novel autoantigens for diabetogenic CD4 T cells in autoimmune diabetes. Immunol Res (2013) 0.82
Amplification of autoimmune disease by infection. Arthritis Res Ther (2005) 0.81
Prevalence and clinical significance of antibodies to citrullinated fibrinogen (ACF) in Chinese patients with rheumatoid arthritis. Clin Rheumatol (2007) 0.81
A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for autoantibody production in rheumatoid arthritis. Arthritis Res Ther (2007) 0.81
Antibodies to citrullinated peptides in tuberculosis. Clin Rheumatol (2013) 0.80
Diagnostic value and clinical significance of anti-CCP in patients with advanced rheumatoid arthritis. J Natl Med Assoc (2005) 0.80
Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open (2016) 0.78
Characterisation of hand small joints arthropathy using high-resolution MRI--limited discrimination between osteoarthritis and psoriatic arthritis. Eur Radiol (2013) 0.78
Molecular Interactions Governing Autoantigen Presentation in Type 1 Diabetes. Curr Diab Rep (2015) 0.78
Diagnostic performance and predictive value of rheumatoid factor, anti-cyclic-citrullinated peptide antibodies and HLA-DRB1 locus genes in rheumatoid arthritis. Int Arch Med (2008) 0.78
Anti-carbamylated Protein Antibody Levels Correlate with Anti-Sa (Citrullinated Vimentin) Antibody Levels in Rheumatoid Arthritis. J Rheumatol (2015) 0.78
The Autophagy Level Is Increased in the Synovial Tissues of Patients with Active Rheumatoid Arthritis and Is Correlated with Disease Severity. Mediators Inflamm (2017) 0.77
Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis--cross-sectional study and literature review. J Med Life (2013) 0.77
Diagnostic and prognostic values of anti glucose-6-phosphate isomerase antibodies in community-recruited patients with very early arthritis. Clin Exp Immunol (2004) 0.77
Post-translational modifications of the major linear epitope 169-190aa of Ro60 kDa autoantigen alter the autoantibody binding. Clin Exp Immunol (2006) 0.76
Insights from populations at risk for the future development of classified rheumatoid arthritis. Rheum Dis Clin North Am (2014) 0.76
Autoantibodies in normals--the value of predicting rheumatoid arthritis. Arthritis Res Ther (2004) 0.76
Is rheumatoid factor still a superior test for the diagnosis of rheumatoid arthritis? Rheumatol Int (2010) 0.76
A comparison of performance of anti-cyclic citrullinated peptide 2 and citrullinated protein antibodies in the diagnosis of rheumatoid arthritis in Iranian patients. Rheumatol Int (2009) 0.75
Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis for Function and Pain is Affected by Rheumatoid Factor. Open Rheumatol J (2014) 0.75
Anti-CCP Antibodies Are Not Associated with Familial Mediterranean Fever in Childhood. Int J Rheumatol (2013) 0.75
[Austrian expert opinion on the standard for expert assessment of course of illness in patients with chronic polyarthritis (rheumatoid arthritis)]. Wien Klin Wochenschr (2008) 0.75
Second generation automated anti-CCP test better predicts the clinical diagnosis of rheumatoid arthritis. J Clin Immunol (2011) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum (2000) 8.64
Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest (1998) 6.92
HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens (1992) 6.87
The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol (1999) 3.22
The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum (1998) 2.74
The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol (1994) 2.44
Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol (1991) 2.43
The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest (1995) 2.37
Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis Rheum (1992) 1.90
Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol (1996) 1.85
Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum (1999) 1.78
Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology (Oxford) (1999) 1.67
Immunoblotting detection of autoantibodies to human epidermis filaggrin: a new diagnostic test for rheumatoid arthritis. J Rheumatol (1998) 1.59
Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum (1989) 1.48
Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol (1993) 1.46
Diagnostic value of antibodies to filaggrin in rheumatoid arthritis. J Rheumatol (1998) 1.32
Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides. Ann Rheum Dis (1999) 1.30
Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest (1992) 1.26
Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol (1999) 1.25
Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol (1993) 1.20
Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay. Int Arch Allergy Immunol (1998) 1.17
Detection and expression of a cDNA clone that encodes a polypeptide containing two inhibitory domains of human calpastatin and its recognition by rheumatoid arthritis sera. J Clin Invest (1995) 1.15
Characterisation of the rat oesophagus epithelium antigens defined by the so-called 'antikeratin antibodies', specific for rheumatoid arthritis. Ann Rheum Dis (1993) 1.13
Association of HLA alleles and clinical features in patients with synovitis of recent onset. Arthritis Rheum (1999) 1.11
Antifilaggrin antibodies in recent-onset arthritis. Scand J Rheumatol (1999) 1.11
Autoantibodies predicting the outcome of rheumatoid arthritis: evaluation in two subsets of patients according to severity of radiographic damage. Ann Rheum Dis (1997) 1.09
Rheumatoid arthritis associated autoimmune systems. J Rheumatol (1998) 0.89
Anti-RA 33 as a marker antibody of rheumatoid arthritis in a Finnish population. Clin Exp Rheumatol (1994) 0.89
Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell (1999) 19.48
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (1984) 17.70
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
The impact of computerized physician order entry on medication error prevention. J Am Med Inform Assoc (1999) 14.47
Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science (2001) 11.56
Integration of cytogenetic landmarks into the draft sequence of the human genome. Nature (2001) 10.96
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med (1994) 8.21
Sequence and analysis of chromosome 2 of the plant Arabidopsis thaliana. Nature (1999) 8.04
Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature (1998) 7.43
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis (2008) 6.97
Guided medication dosing for inpatients with renal insufficiency. JAMA (2001) 6.25
The earliest angiosperms: evidence from mitochondrial, plastid and nuclear genomes. Nature (1999) 5.85
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev (2000) 5.40
Odds ratio or relative risk for cross-sectional data? Int J Epidemiol (1994) 5.27
Peripheral Nerves in Chronic Atrophic Arthritis. Am J Pathol (1942) 5.21
Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science (1994) 5.20
Lesions of Skeletal Muscles in Rheumatoid Arthritis: Nodular Polymyositis. Am J Pathol (1946) 4.86
Prevention of fat-induced insulin resistance by salicylate. J Clin Invest (2001) 4.74
Structure and functional expression of a human interleukin-8 receptor. Science (1991) 4.74
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) (2004) 4.56
Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res (1995) 4.52
Estimation of prevalence rate ratios for cross sectional data: an example in occupational epidemiology. Br J Ind Med (1993) 4.41
Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA (2000) 4.41
A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. Am J Hum Genet (2001) 4.17
Identification of heregulin, a specific activator of p185erbB2. Science (1992) 4.17
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med (1986) 4.01
Transgene and transposon silencing in Chlamydomonas reinhardtii by a DEAH-box RNA helicase. Science (2000) 3.84
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A (1998) 3.73
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science (1982) 3.67
Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature (1997) 3.64
Exact confidence interval of the SMR based on prevalence data. Int J Epidemiol (1994) 3.62
Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med (1998) 3.59
Proliferation of mutators in A cell population. J Bacteriol (1997) 3.55
Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA (2001) 3.55
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis (2005) 3.53
MARCKS is an actin filament crosslinking protein regulated by protein kinase C and calcium-calmodulin. Nature (1992) 3.49
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res (1997) 3.38
Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). I. Characterization of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions by flow cytometric analysis. Cell Immunol (1984) 3.36
Dietary effects on breast-cancer risk in Singapore. Lancet (1991) 3.32
The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye Res (2001) 3.30
Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther (2013) 3.29
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
A case of concomitant tuberculosis and sarcoidosis with mycobacterial DNA present in the sarcoid lesion. Chest (1998) 3.25
T-DNA insertional mutagenesis for functional genomics in rice. Plant J (2000) 3.25
Inter-RNA interaction of phage phi29 pRNA to form a hexameric complex for viral DNA transportation. Mol Cell (1998) 3.21
The H2O2 stimulon in Saccharomyces cerevisiae. J Biol Chem (1998) 3.19
The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med (1998) 3.16
Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J Exp Med (1996) 3.16
A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet (2004) 3.05
Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M. Arch Intern Med (1998) 3.01
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol (1990) 2.99
Using computerized data to identify adverse drug events in outpatients. J Am Med Inform Assoc (2001) 2.98
Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med (1978) 2.92
Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord (2003) 2.89
Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun (1995) 2.87
Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol (2001) 2.86
Evidence-based disease management. JAMA (1997) 2.85
IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J (2001) 2.84
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene (2008) 2.83
Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med (1999) 2.81
Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med (2001) 2.77
Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc Natl Acad Sci U S A (2006) 2.77
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
FIERY1 encoding an inositol polyphosphate 1-phosphatase is a negative regulator of abscisic acid and stress signaling in Arabidopsis. Genes Dev (2001) 2.73
Intraglottal pressure profiles for a symmetric and oblique glottis with a divergence angle of 10 degrees. J Acoust Soc Am (2001) 2.72
Smaller inner ear sensory epithelia in Neurog 1 null mice are related to earlier hair cell cycle exit. Dev Dyn (2005) 2.71
Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res (2001) 2.68
Protein structure prediction by global optimization of a potential energy function. Proc Natl Acad Sci U S A (1999) 2.66
The Otto E. Aufranc Award: The role of labral lesions to development of early degenerative hip disease. Clin Orthop Relat Res (2001) 2.63
Regulation by phosphorylation of reversible association of a myristoylated protein kinase C substrate with the plasma membrane. Nature (1991) 2.60
Qualitative interview study of communication between parents and children about maternal breast cancer. BMJ (2000) 2.60
Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis. Am J Pathol (1999) 2.59
NODULAR POLYMYOSITIS IN RHEUMATOID ARTHRITIS. Science (1945) 2.59
Mixed connective tissue disease: to be or not to be? Arthritis Rheum (1998) 2.58
Correlation of the highest-energy cosmic rays with nearby extragalactic objects. Science (2007) 2.57
Genome-wide search for asthma susceptibility loci in a founder population. The Collaborative Study on the Genetics of Asthma. Hum Mol Genet (1998) 2.57
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Forces exerted by locomoting cells. Semin Cell Biol (1994) 2.53
A delicate balance: homeostatic control of copper uptake and distribution. J Nutr (1999) 2.52
Specific cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein is a characteristic biochemical feature of apoptotic cell death. J Biol Chem (1994) 2.51
Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. J Rheumatol (1998) 2.50
Characterization of recombinant pig enamelysin activity and cleavage of recombinant pig and mouse amelogenins. J Dent Res (1999) 2.50
Yoga-based intervention for carpal tunnel syndrome: a randomized trial. JAMA (1998) 2.50
Is it mandatory to examine synovial fluids promptly after arthrocentesis? Arthritis Rheum (1989) 2.49
Family history and perceived vulnerability to some common diseases: a study of young people and their parents. J Med Genet (1996) 2.49
Local application of retinoic acid to the limb bond mimics the action of the polarizing region. Nature (1982) 2.48
A mutant insulin receptor with defective tyrosine kinase displays no biologic activity and does not undergo endocytosis. J Biol Chem (1987) 2.48
Association of markers of systemic inflammation, C reactive protein, serum amyloid A, and fibrinogen, with socioeconomic status. J Epidemiol Community Health (2003) 2.46
Phytochrome signalling is mediated through nucleoside diphosphate kinase 2. Nature (1999) 2.46
Sickle-cell trait as a risk factor for sudden death in physical training. N Engl J Med (1987) 2.44